Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

BACKGROUND: Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearing radiolabelled hapten peptide improves tumour localisation. The primary goals of this first pretargeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoffelen, R, Boerman, O C, Goldenberg, D M, Sharkey, R M, van Herpen, C M L, Franssen, G M, McBride, W J, Chang, C-H, Rossi, E A, van der Graaf, W T A, Oyen, W J G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749562/
https://www.ncbi.nlm.nih.gov/pubmed/23860529
http://dx.doi.org/10.1038/bjc.2013.376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749562/
https://www.ncbi.nlm.nih.gov/pubmed/23860529
http://dx.doi.org/10.1038/bjc.2013.376

Ejemplares similares